Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data

BackgroundChronic obstructive pulmonary disease (COPD) is the fourth leading cause of death among US adults and is projected to be the third by 2020. In anticipation of the increasing burden imposed on healthcare systems and payers by patients with COPD, a means of identifying COPD patients who incur higher healthcare utilization and costs is needed.MethodsThis retrospective, cross-sectional analysis of US managed care administrative claims data describes a practical way to identify COPD patients. We analyze 7.79 million members for potential inclusion in the COPD cohort, who were continuously eligible during a 1-year study period. A younger commercial population (7.7 million) is compared with an older Medicare population (0.115 million). We outline a novel approach to stratifying COPD patients using "complexity" of illness, based on occurrence of claims for given comorbid conditions. Additionally, a unique algorithm was developed to identify and stratify COPD exacerbations using claims data.ResultsA total of 42,565 commercial (median age 56 years; 51.4% female) and 8507 Medicare patients (median 75 years; 53.1% female) were identified as having COPD. Important differences were observed in comorbidities between the younger commercial versus the older Medicare population. Stratifying by complexity, 45.0%, 33.6%, and 21.4% of commercial patients and 36.6%, 35.8%, and 27.6% of older patients were low, moderate, and high, respectively. A higher proportion of patients with high complexity disease experienced multiple (≥2) exacerbations (61.7% commercial; 49.0% Medicare) than patients with moderate- (56.9%; 41.6%), or low-complexity disease (33.4%; 20.5%). Utilization of healthcare services also increased with an increase in complexity.ConclusionIn patients with COPD identified from Medicare or commercial claims data, there is a relationship between complexity as determined by pulmonary and non-pulmonary comorbid conditions and the prevalence of exacerbations and utilization of healthcare services. Identification of COPD patients at highest risk of exacerbations using complexity stratification may facilitate improved disease management by targeting those most in need of treatment.

[1]  Claudio Pedone,et al.  Comorbidities of chronic obstructive pulmonary disease , 2011, Current opinion in pulmonary medicine.

[2]  Joan B Soriano,et al.  The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. , 2003, Chest.

[3]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[4]  D. Coultas,et al.  Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. , 2000, Archives of internal medicine.

[5]  D. Postma,et al.  Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[6]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[7]  Sylvia E. Rosas,et al.  MORBIDITY AND MORTALITY , 2010 .

[8]  C. Camargo,et al.  Mortality after an Emergency Department Visit for Exacerbation of Chronic Obstructive Pulmonary Disease , 2006, COPD.

[9]  E. Rönmark,et al.  The costs of exacerbations in chronic obstructive pulmonary disease (COPD). , 2002, Respiratory medicine.

[10]  P. Villari,et al.  Comorbidity, Hospitalization, and Mortality in COPD: Results from a Longitudinal Study , 2010, Lung.

[11]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[12]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[13]  D. Mannino,et al.  Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. , 2006, Respiratory medicine.

[14]  A. Swensen,et al.  The Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease and Exacerbation Definition: A Review , 2010, COPD.

[15]  G. Tognoni,et al.  Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population , 2007, International journal of chronic obstructive pulmonary disease.

[16]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[17]  M. Young,et al.  Health services research , 2008, Journal of General Internal Medicine.

[18]  D. Mannino,et al.  Lung function decline and outcomes in an elderly population , 2005, Thorax.

[19]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[20]  E. R. Sutherland,et al.  Predictors of rehospitalization and death after a severe exacerbation of COPD. , 2007, Chest.

[21]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[22]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[23]  T. Wilt,et al.  Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline , 2007, Annals of Internal Medicine.

[24]  E. R. Mcfadden,et al.  Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. , 1997, American journal of respiratory and critical care medicine.